Market Spotlight: Cervical Cancer
Market Spotlight: Cervical Cancer
$1,318.00
This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Cervical Cancer market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, licensing and acquisition deals, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were 564,900 incident cases of cervical cancer in females worldwide, and expects that number to increase to 618,400 incident cases by 2026.
- Approved drugs for cervical cancer target vascular endothelial growth factor, topoisomerase I, programmed death-1 receptor (PD-1)/programmed death ligands (PD-L1 and PD-L2), the immune system, reactive oxygen species/free radicals, and tissue factor. The majority of these therapies are administered via the intravenous route.
- The majority of the industry-sponsored drugs in active clinical development for cervical cancer are in Phase II, with two drugs in the NDA/BLA stage.
- Therapies in development for cervical cancer focus on a wide variety of targets. The majority of the pipeline drugs are administered via the intravenous route, with the remainder being oral, subcutaneous, intramuscular, intravesical, and intranasal formulations.
- High-impact upcoming events for drugs in the cervical cancer space comprise topline Phase I/II trial results for tiragolumab, topline Phase II trial results for bintrafusp alfa, topline Phase III trial results for Imfinzi, and expected PDUFA dates for biosimilar bevacizumab (Mylan/Biocon) and balstilimab.
- The overall likelihood of approval of a Phase I solid tumors asset is 5.3%, and the average probability a drug advances from Phase III is 42.3%. Drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for cervical cancer have been in the early and mid-phases of development, with 94% of trials in Phase I–II, and only 6% in Phase III–IV.
- The US has a substantial lead in the number of cervical cancer clinical trials globally. Spain leads the major European markets, while China has the top spot in Asia.
- Roche and Pfizer have the highest number of completed clinical trials for cervical cancer, with 17 trials each. Merck & Co leads the industry sponsors with the highest overall number of clinical trials for cervical cancer, followed closely by AstraZeneca.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiotherapy
9 Chemotherapy
10 Targeted therapy
10 Immunotherapy
11 EPIDEMIOLOGY
14 MARKETED DRUGS
17 PIPELINE DRUGS
25 RECENT EVENTS AND ANALYST OPINION
25 Tivdak for Cervical Cancer (September 19, 2021)
27 Keytruda for Cervical Cancer (September 18, 2021)
29 Keytruda for Cervical Cancer (June 22, 2021)
31 Libtayo for Cervical Cancer (May 12, 2021)
32 Libtayo for Cervical Cancer (March 15, 2021)
34 Tisotumab Vedotin for Cervical Cancer (September 21, 2020)
36 Balstilimab for Cervical Cancer (September 18, 2020)
38 Tisotumab Vedotin for Cervical Cancer (June 29, 2020)
40 GX-188E for Cervical Cancer (April 27, 2020)
43 KEY UPCOMING EVENTS
44 KEY REGULATORY EVENTS
44 Seagen/Genmab’s Tivdak Set To Take On Merck’s Keytruda
44 Agenus May Get Holiday Cheer
44 Tisotumab Vedotin Targets Second-Line Cervical Cancer Claim
44 Agenus Kicks Off Rolling BLA For Balstilimab
46 PROBABILITY OF SUCCESS
47 LICENSING AND ASSET ACQUISITION DEALS
47 Biomm Backs Bio-Thera’s Brazilian Bevacizumab
48 REVENUE OPPORTUNITY
49 CLINICAL TRIAL LANDSCAPE
50 Sponsors by status
51 Sponsors by phase
52 Recent events
55 BIBLIOGRAPHY
56 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of cervical cancer, 2017–26
17 Figure 2: Overview of pipeline drugs for cervical cancer in the US
17 Figure 3: Pipeline drugs for cervical cancer, by company
18 Figure 4: Pipeline drugs for cervical cancer, by drug type
18 Figure 5: Pipeline drugs for cervical cancer, by classification
27 Figure 6: Tivdak for Cervical Cancer (September 19, 2021): Phase I/II – innovaTV 205
29 Figure 7: Keytruda for Cervical Cancer (September 18, 2021): Phase III – KEYNOTE-826 (w/Chemotherapy, 1L)
31 Figure 8: Keytruda for Cervical Cancer (June 22, 2021): Phase III – KEYNOTE-826 (w/Chemotherapy, 1L)
32 Figure 9: Libtayo for Cervical Cancer (May 12, 2021): Phase III – vs. Chemotherapy
34 Figure 10: Libtayo for Cervical Cancer (March 15, 2021): Phase III – vs. Chemotherapy
36 Figure 11: Tisotumab Vedotin for Cervical Cancer (September 21, 2020): Phase II – innovaTV 204
38 Figure 12: Balstilimab for Cervical Cancer (September 18, 2020): Phase II – RaPiDS (+/- AGEN1884, 2nd Line)
40 Figure 13: Tisotumab Vedotin for Cervical Cancer (June 29, 2020): Phase II – innovaTV 204
42 Figure 14: GX-188E for Cervical Cancer (April 27, 2020): Phase Ib/IIa – w/Pembrolizumab (Korea)
43 Figure 15: Key upcoming events in cervical cancer
46 Figure 16: Probability of success in the solid tumors pipeline
49 Figure 17: Clinical trials in cervical cancer
49 Figure 18: Top 10 drugs for clinical trials in cervical cancer
50 Figure 19: Top 10 companies for clinical trials in cervical cancer
50 Figure 20: Trial locations in cervical cancer
51 Figure 21: Cervical cancer trials status
52 Figure 22: Cervical cancer trials sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of cervical cancer, 2017–26
15 Table 2: Marketed drugs for cervical cancer
19 Table 3: Pipeline drugs for cervical cancer in the US
25 Table 4: Tivdak for Cervical Cancer (September 19, 2021)
28 Table 5: Keytruda for Cervical Cancer (September 18, 2021)
30 Table 6: Keytruda for Cervical Cancer (June 22, 2021)
31 Table 7: Libtayo for Cervical Cancer (May 12, 2021)
33 Table 8: Libtayo for Cervical Cancer (March 15, 2021)
35 Table 9: Tisotumab Vedotin for Cervical Cancer (September 21, 2020)
37 Table 10: Balstilimab for Cervical Cancer (September 18, 2020)
39 Table 11: Tisotumab Vedotin for Cervical Cancer (June 29, 2020)
41 Table 12: GX-188E for Cervical Cancer (April 27, 2020)
48 Table 13: Historical global sales, by drug ($m), 2016–20
48 Table 14: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Esophageal Cancer 
Sign up to the